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Letrozole is a drug used in the treatment of postmenopausal women with breast and ovarian tumours. There is no evidence in the lit-
erature indicating its use in treating gastric cancer. We present a 68 year old lady admitted from the emergency department with weight 
loss, malaise and anaemia. Investigations confirmed the presence of two different primary tumours in the left breast and the stomach. 
Following that this patient with oestrogen receptor positive breast cancer and oestrogen receptor negative gastric cancer was treated with 
letrozole for her breast cancer followed by a gastric resection. Independent histology by two pathologists pre-operatively diagnosed gastric 
adenocarcinoma. Post-operatively, independent analysis of the resected stomach, omentum and lymph nodes revealed no evidence of 
gastric cancer. Therefore we conclude that there is a possibility of letrozole having an effect on gastric cancer. Further studies are needed.
Key Words: Letrozole; Stomach neoplasms; Remission, spontaneous
Case Report J Gastric Cancer 2011;11(3):180-184 y http://dx.doi.org/10.5230/jgc.2011.11.3.180
Correspondence to: Ahmed EL Hadi
Department of General Surgery, Nevill Hall Hospital, Brecon Road, 
Abergavenny, Wales, United Kingdom, NP7 7EG
Tel: +01873 732503, Fax: +01873 732746
E-mail: ahmed.elhadi@gmail.com
Received June 29, 2011
Revised September 15, 2011
Accepted September 15, 2011
Copyrights © 2011 by The Korean Gastric Cancer Association www.jgc-online.org
 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/3.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction
1. Letrazole
Aromatase inhibitors (AI) are a class of drugs used in the treat-
ment of breast and ovarian cancer in postmenopausal women. 
Estrogen has a great role on the progression of breast cancer, and 
studies have shown that exposure to estrogens increases the risk 
of breast cancer(1) therefore therapeutic agents targeting estrogen 
synthesis & Estrogen receptors have made a huge difference to the 
treatment of breast cancer. Letrozole is a very potent and selective 
AI that leads to the inhibition of the enzyme activity of intracel-
lular aromatase at the major sites where it is found.(2) Aromatase is 
expressed primarily in the ovary and also in central and peripheral 
tissues, fat, muscle, liver, and breast. Letrozole is only effective in 
postmenopausal women in whom estrogen is produced predomi-
nantly by the adrenals. Whilst in premenopausal women estrogen 
is produced in the ovaries and letrozole is ineffective. Randomized 
clinical trials have demonstrated the clinical benefits of letrozole 
across the spectrum of hormone-responsive breast cancer in post-
menopausal women.(3,4)
2. Differentiating primary gastric cancer from meta-
static breast cancer to stomach
It may be very difficulty to differentiate between primary gastric 
tumours from metastatic breast cancer to the stomach on clini-
cal, endoscopic, radiological and histopathological features(5,6) 
detailed immunohistochemical analysis may be the only consistent 
method for differentiating between metastatic and primary gastric 
carcinoma. Although oestrogen and progesterone receptor positiv-
ity in the gastric biopsies suggest breast cancer metastasis to the 
stomach, it is worth noting that oestrogen and progesterone recep-
tor positivity have been reported in 32% and 12% of patients with 
primary gastric cancer.(7) However, these findings are based upon 
studies using first-generation antibodies against Oestrogen receptor 
β (ERβ) which are no longer used in standard practice. Taal et al 
investigated whether immunohistochemical detection with second-
generation antibodies against Oestrogen receptor α (ERα) can be 
used to diagnose gastric metastasis of breast carcinoma(8) and they An Effect of Letrozole on Gastric Cancer?
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concluded that ERα expression can be reliably used to diagnose 
gastric metastasis of breast cancer. They also investigated if the 
expression pattern of E-cadherin could help in the differentiat-
ing the diagnosis of primary gastric cancer versus metastatic breast 
carcinoma. In their study absence of E-cadherin staining was sig-
nificantly related to metastatic breast carcinoma. Therefore absence 
of E-cadherin expression in an adenocarcinoma in a gastric biopsy 
should raise the possibility of metastatic breast carcinoma and ER
α positivity can be reliably used to diagnose gastric metastasis of 
breast carcinoma. 
Positive monoclonal staining with gross cystic disease fluid 
protein-15 has been found to be a sensitive (55~76%) and specific 
(95~100%) marker to correctly identify a malignant lesion as meta-
static breast carcinoma.(9-12)
Table 1 summarizes the Immunohistochemical methods of Dif-
ferentiating Primary gastric cancer from Metastatic gastric cancer. 
To summarize, in patients with a history of breast cancer, one 
should suspect the possibility of breast cancer metastasis to the 
stomach when new primary gastric cancer is diagnosed. Complete 
histopathological and immunohistochemical analysis of the gastric 
biopsies and comparison with the original breast cancer pathology 
is important.(13)
Case Report
We present a 68 year old lady who was admitted as an emer-
gency with malaise, weight loss & haemoglobin of 3 g/dl. She had 
not presented previously as she had been caring for her terminally 
ill husband .She underwent a gastroscopy to investigate her anae-
mia which revealed a large size malignant appearing gastric ulcer at 
the antrum, this was biopsied and computerized tomography (CT) 
of the thorax and abdomen was requested.
The CT Thorax and Abdomen scan showed thickening of the 
gastric antrum (Fig. 1) in additional to widespread lymphadenopa-
thy in the greater omentum/mesentery (Fig. 2), the appearances 
were suggestive of gastric cancer. The CT scan also showed a co-
incidental finding of a left breast cancer (Fig. 3) with left axillary 
lymphadenopathy (Fig. 4). On further questioning the patient had 
been aware of the breast lump for 18 months but did not seek 
medical advice. Following the CT she underwent a mammogram 
which confirmed the left side breast cancer (Fig. 5).
1. Biopsies of the left breast lump showed 
Invasive ductal carcinoma grade 2 (Fig. 6). The Clinical tumour 
node metastasis (TNM) classification was T2, N1, M0. 
The tumour cells are diffusely and strongly positive for oestro-
gen receptors, negative for progesterone receptors, positive for E-
cadherin which is consistent with an invasive ductal carcinoma and 
Herceptin 2 receptors positive.
Table 1. To summarize the difference between primary stomach 
cancer and metastatic breast carcinoma of the stomach
Primary 
stomach cancer
Metastatic breast 
carcinoma of stomach
 ERα  Negative  Positive or negative
 E-cadherin  Positive  Negative
 GCDFP-15  Negative  Positive
ERα = oestrogen receptor α; GCDFP-15 = gross cystic disease fl  uid 
protein-15.
Fig. 1. CT abdomen showing thickening of the gastric antrum which 
measured approximately 19.3 mm. CT = computerized tomography.
Fig. 2. CT abdomen demonstrates the mesenteric lymphadenopathy, 
showing two lymph nodes measuring 8.6 and 9.3 mm. CT = computer-
ized tomography.Ahmed EL Hadi, et al.
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2. Biopsies of the stomach showed
An adenocarcinoma of the stomach (Fig. 7) and a second opin-
ion was sought with the Professor of Gastrointestinal histology who 
concluded an adenocarcinoma of the stomach. The tumour was 
oestrogen receptor negative. The clinical TNM classification was 
T2, N3, M0. 
This was all discussed in the Multidisciplinary team meeting 
and it was that in evidence of oestrogen receptors being positive 
in the breast tumour and negative in the stomach tumour that the 
patient most likely had two primary tumours. 
3. Treatment
The breast tumour was treated with letrozole 2.5 mg daily as 
long term treatment. Surgical treatment was discussed with the 
patient however she wanted to await the outcome of her stomach 
cancer. Following that the patient then underwent a staging lapa-
roscopy followed by a subtotal D2 gastrectomy with roux en Y 
reconstruction. At laparotomy it was found that the antral ulcer had 
invaded the pancreas over a 2 cm wide area, after further intraop-
erative consideration, the resection proceeded with excision of a 
cuff of pancreatic tissue. She made a good postoperative recovery. 
Postoperatively the histology showed a large gastric ulcer with 
inflammation and fibrosis with NO evidence of malignancy. 22 
lymph nodes were resected which were all negative for malignancy. 
Fig. 3. CT thorax showing an incidental finding of a left side breast 
tumour measuring 18.2 mm as demonstrated on the scan. CT = com-
puterized tomography.
Fig. 4. CT thorax showing left   axillary lymphadenopathy, one of the 
lymph node measured 11 mm as shown on the scan. CT = computer-
ized tomography.
Fig. 5. Left   breast mammogram showing left   side breast cancer.
Fig. 6. Left breast biopsy (Formalin fixed paraffin embedded tissue 
stained with haematoxylin-eosin) showing invasive ductal carcinoma 
of the breast grade 2.An Effect of Letrozole on Gastric Cancer?
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After the patient recovered from the gastrectomy, surgical treat-
ment of her breast cancer was discussed again with the patient, 
however she refused and opted to continue with letrozole treat-
ment. She has been seen regularly in the outpatient clinic following 
the operation and in her last clinic visit, which was approximately 
14 months postoperatively, she has gained 16 kg in weight and the 
palpable tumour in her left breast has significantly reduced in size. 
She also expressed her satisfaction with her treatment up to date 
and is still not keen on surgical treatment, therefore the letrozole 
has been continued at 2.5 mg daily dose with a view of reviewing 
the patient in another 6 months. She had a CT scan of her abdo-
men which showed no evidence of recurrence of the gastric cancer. 
Discussion
The original gastric biopsies of the patient showing invasive 
adenocarcinoma of the stomach, which was confirmed by two 
independent histopathologists being ER receptor negative is more 
likely to be a primary gastric tumour. Unfortunately Immuno-
histochemical analysis could not be carried out as the samples were 
cut out of the block. 
Irrespective of whether the gastric cancer was primary or meta-
static from breast cancer, in our patient following the resection of 
the stomach, there was no evidence of malignancy in the stomach 
and none in the 22 resected lymph nodes. After careful analysis 
and review of the patient we have concluded that this could be due 
to three possibilities: 1) The only treatment instigated between di-
agnosis and resection of the gastric tumour was letrozole so, did le-
trozole have an effect on the gastric cancer. As we mentioned pre-
viously the main mechanism of action of letrozole is an aromatase 
inhibitor. We suggest that their might be other intracellular signal-
ing pathways supported by evidence suggesting down regulation of 
genes associated with cell cycle and proliferation following letrozole 
treatment these changes could alter not only cellular expression 
but secondary consequences of cell death and clonal selection, in 
addition to longer term changes shown to alter vascularization, 
remodeling and the inflammatory response at the mitochondrial 
and extracellular matrix level.(14) This will need further research 
and studies to determine if letrozole could have a therapeutic ef-
fect on gastrointestinal tumours. 2) Did the gastric cancer undergo 
spontaneous remission? This is unlikely however there are a few 
published cases in literature and the mechanism is not clearly un-
derstood.(15) 3) Sampling error: Evidence of artefact or sampling 
error were investigated and double checked by two independent 
pathologists and discussed in the report and none were identified.
We would also like to highlight the importance of conducting 
Immunohistochemical analysis when patients are diagnosed with 
stomach cancer and are also found to have Breast cancer. Unfortu-
nately in our case Immuno-histochemical analysis was not carried 
out as the samples were cut out of the block. As we have discussed 
earlier Immunohistochemical analysis is very useful in differentiat-
ing between primary stomach cancers from metastatic breast carci-
noma of the stomach and hence the management of these patients. 
Conclusion
In conclusion, a patient with oestrogen receptor positive breast 
cancer and oestrogen receptor negative gastric cancer was treated 
with letrozole and gastric resection. Independent histology by two 
pathologists pre-operatively diagnosed gastric adenocarcinoma. 
Fig. 7. Gastric biopsy (Formalin fi  xed paraffi   n embedded tissue stained with haematoxylin-eosin) showing gastric ulceration with invasive adeno-
carcinoma of the stomach.Ahmed EL Hadi, et al.
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Post-operatively, independent analysis of the resected stomach, 
omentum, pancreas and lymph nodes revealed no evidence of gas-
tric cancer. This suggests the possibility of letrozole having an ef-
fect on gastric cancer. Further studies are needed.
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